Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 61.17 Million USD | 32.54% |
| 2022 | 46.15 Million USD | -11.24% |
| 2021 | 51.99 Million USD | 18.51% |
| 2020 | 43.87 Million USD | -7.27% |
| 2019 | 47.31 Million USD | 11.88% |
| 2018 | 42.29 Million USD | 30.23% |
| 2017 | 32.47 Million USD | 1.52% |
| 2016 | 31.98 Million USD | 54.72% |
| 2015 | 20.67 Million USD | 196.18% |
| 2014 | 6.98 Million USD | 77466.67% |
| 2013 | 9000.00 USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 16.57 Million USD | -15.62% |
| 2024 Q2 | 20.07 Million USD | 21.14% |
| 2023 Q4 | 19.64 Million USD | -4.69% |
| 2023 Q3 | 20.6 Million USD | 36.35% |
| 2023 FY | 61.17 Million USD | 32.54% |
| 2023 Q1 | 11.51 Million USD | -3.24% |
| 2023 Q2 | 15.11 Million USD | 31.21% |
| 2022 Q2 | 12.43 Million USD | 21.73% |
| 2022 Q4 | 11.9 Million USD | 2.69% |
| 2022 Q1 | 10.21 Million USD | -14.8% |
| 2022 Q3 | 11.59 Million USD | -6.8% |
| 2022 FY | 46.15 Million USD | -11.24% |
| 2021 Q4 | 11.99 Million USD | 14.61% |
| 2021 Q2 | 19.89 Million USD | 106.07% |
| 2021 Q1 | 9.65 Million USD | -18.08% |
| 2021 FY | 51.99 Million USD | 18.51% |
| 2021 Q3 | 10.46 Million USD | -47.39% |
| 2020 Q1 | 12.6 Million USD | -16.36% |
| 2020 Q2 | 8.55 Million USD | -32.16% |
| 2020 Q3 | 10.93 Million USD | 27.86% |
| 2020 Q4 | 11.78 Million USD | 7.74% |
| 2020 FY | 43.87 Million USD | -7.27% |
| 2019 Q2 | 9.68 Million USD | -14.25% |
| 2019 Q1 | 11.29 Million USD | -18.12% |
| 2019 Q4 | 15.07 Million USD | 33.75% |
| 2019 FY | 47.31 Million USD | 11.88% |
| 2019 Q3 | 11.27 Million USD | 16.42% |
| 2018 Q3 | 10.17 Million USD | 3.75% |
| 2018 FY | 42.29 Million USD | 30.23% |
| 2018 Q1 | 8.52 Million USD | 5.27% |
| 2018 Q2 | 9.8 Million USD | 14.99% |
| 2018 Q4 | 13.78 Million USD | 35.56% |
| 2017 FY | 32.47 Million USD | 1.52% |
| 2017 Q4 | 8.09 Million USD | -7.39% |
| 2017 Q3 | 8.74 Million USD | -8.9% |
| 2017 Q2 | 9.59 Million USD | 59.16% |
| 2017 Q1 | 6.03 Million USD | -38.16% |
| 2016 Q4 | 9.75 Million USD | 24.85% |
| 2016 FY | 31.98 Million USD | 54.72% |
| 2016 Q1 | 5.42 Million USD | 1.29% |
| 2016 Q3 | 7.81 Million USD | -13.21% |
| 2016 Q2 | 9 Million USD | 65.98% |
| 2015 Q4 | 5.35 Million USD | -14.57% |
| 2015 FY | 20.67 Million USD | 196.18% |
| 2015 Q1 | 3.65 Million USD | 126.88% |
| 2015 Q2 | 5.4 Million USD | 47.74% |
| 2015 Q3 | 6.26 Million USD | 16.06% |
| 2014 Q2 | 1.81 Million USD | 19.34% |
| 2014 Q4 | 1.61 Million USD | -20.87% |
| 2014 Q3 | 2.03 Million USD | 12.24% |
| 2014 Q1 | 1.52 Million USD | 276.74% |
| 2014 FY | 6.98 Million USD | 77466.67% |
| 2013 FY | 9000.00 USD | 0.0% |
| 2013 Q2 | 168 Thousand USD | 0.0% |
| 2013 Q3 | 701 Thousand USD | 317.26% |
| 2013 Q4 | -860 Thousand USD | -222.68% |
| 2013 Q1 | - USD | -100.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 5000.00 USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | 73 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 73.06 Million USD | 16.282% |
| Theratechnologies Inc. | 62.12 Million USD | 1.544% |
| Safety Shot Inc | -74.45 Thousand USD | 82254.801% |
| Cosmos Health Inc. | 4.34 Million USD | -1306.346% |
| Cronos Group Inc. | 6.99 Million USD | -774.995% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 86.134% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 20288.119% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 80.254% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -506.973% |
| ProPhase Labs, Inc. | 16.23 Million USD | -276.686% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1189.146% |
| Dynavax Technologies Corporation | 182.11 Million USD | 66.412% |
| Radius Health, Inc. | 307.71 Million USD | 80.121% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -10942.094% |
| Alvotech | -69.42 Million USD | 188.113% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -633.526% |
| Alpha Teknova, Inc. | 10.29 Million USD | -494.114% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 85.795% |
| SCYNEXIS, Inc. | 124.51 Million USD | 50.874% |
| Harrow Health, Inc. | 90.55 Million USD | 32.448% |
| Biofrontera Inc. | 16.62 Million USD | -267.896% |
| DURECT Corporation | 6.83 Million USD | -795.477% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 88.321% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 79.964% |
| OptiNose, Inc. | 62.35 Million USD | 1.899% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1902.834% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -105.6% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -82.674% |
| SIGA Technologies, Inc. | 122.09 Million USD | 49.898% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -46.165% |
| Shineco, Inc. | 882.16 Thousand USD | -6834.053% |
| Phibro Animal Health Corporation | 312.48 Million USD | 80.425% |
| Procaps Group S.A. | 239.56 Million USD | 74.467% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -4598.157% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 8304.263% |
| Viatris Inc. | 6.43 Billion USD | 99.05% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -633.526% |
| Rockwell Medical, Inc. | 8.7 Million USD | -602.78% |
| Incannex Healthcare Limited | 12 Thousand USD | -509650.0% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -12.062% |
| Tilray Brands, Inc. | 223.35 Million USD | 72.613% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 81.246% |
| PetIQ, Inc. | 252.74 Million USD | 75.797% |
| Silver Spike Investment Corp. | 8.1 Million USD | -654.943% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 96.689% |
| Journey Medical Corporation | 52.52 Million USD | -16.468% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1359.498% |
| Assertio Holdings, Inc. | 125.04 Million USD | 51.083% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 898206.005% |
| Embecta Corp. | 749.9 Million USD | 91.843% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2637.989% |
| Procaps Group, S.A. | 239.56 Million USD | 74.467% |
| PainReform Ltd. | -15 Thousand USD | 407900.0% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -125.578% |
| Hempacco Co., Inc. | -1.21 Million USD | 5131.119% |
| Talphera, Inc. | -4.89 Million USD | 1349.642% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 87.524% |
| Alvotech | -69.42 Million USD | 188.113% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 91.379% |
| Kamada Ltd. | 52.59 Million USD | -16.309% |
| Indivior PLC | 907 Million USD | 93.256% |
| Currenc Group, Inc. | 17.35 Million USD | -252.437% |
| Evoke Pharma, Inc. | 4.97 Million USD | -1128.621% |
| Flora Growth Corp. | 17.73 Million USD | -244.853% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2637.989% |
| Evolus, Inc. | 140.52 Million USD | 56.471% |
| HUTCHMED (China) Limited | 453.55 Million USD | 86.513% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 82.216% |
| Akanda Corp. | 111.44 Thousand USD | -54786.091% |